PMID- 17606327
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20191210
IS  - 0306-4530 (Print)
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 32
IP  - 6
DP  - 2007 Jul
TI  - Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not 
      nerve growth factor, during treatment and results in long-term spatial learning 
      deficits.
PG  - 734-45
AB  - In this study, brain derived neurotrophic factor (BDNF) and nerve growth factor 
      (NGF) were examined at five time points [postnatal day (P)11, 15, 20, 21, and 68 
      (the latter with or without behavioral testing)] during and after P11-20 
      (+)-methamphetamine (MA) (10 mg/kg 4 x day) treatment. BDNF in MA-treated animals 
      was elevated on P15 and P20 in the hippocampus but not in the hypothalamus and 
      was unchanged on P11 and P21. On P68 (1 h after Morris water maze testing) 
      MA-treated offspring showed a trend toward higher levels of BDNF in the 
      hippocampus than saline-treated animals. MA treatment increased NGF levels in the 
      hippocampus but only on P20. No effect of MA treatment was observed in the 
      elevated zero maze. MA-treated offspring had increased latencies, cumulative 
      distances, path lengths, and first bearings in the Morris water maze. The 
      findings indicate that early MA exposure induces hippocampal BDNF increases that 
      precede the later emergence of spatial learning deficits.
FAU - Skelton, Matthew R
AU  - Skelton MR
AD  - Division of Neurology, Cincinnati Children's Research Foundation and Department 
      of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
FAU - Williams, Michael T
AU  - Williams MT
FAU - Schaefer, Tori L
AU  - Schaefer TL
FAU - Vorhees, Charles V
AU  - Vorhees CV
LA  - eng
GR  - K01 DA014269-05/DA/NIDA NIH HHS/United States
GR  - T32 ES007051-33/ES/NIEHS NIH HHS/United States
GR  - DA006733/DA/NIDA NIH HHS/United States
GR  - K01 DA014269/DA/NIDA NIH HHS/United States
GR  - T32 ES007051/ES/NIEHS NIH HHS/United States
GR  - ES07051/ES/NIEHS NIH HHS/United States
GR  - R01 DA006733/DA/NIDA NIH HHS/United States
GR  - DA014269/DA/NIDA NIH HHS/United States
GR  - R01 DA006733-17/DA/NIDA NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070702
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
RN  - 44RAL3456C (Methamphetamine)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Corticosterone/blood
MH  - Female
MH  - Hippocampus/drug effects/metabolism
MH  - Hypothalamus/drug effects/metabolism
MH  - Learning/*drug effects
MH  - Male
MH  - Maze Learning/drug effects
MH  - Memory Disorders/*chemically induced
MH  - Methamphetamine/adverse effects/*pharmacology
MH  - Nerve Growth Factors/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spatial Behavior/*drug effects
MH  - Time Factors
PMC - PMC2756096
MID - NIHMS137148
COIS- Conflict of interest The authors certify that they have no conflict of interest 
      pertaining to any aspect of the research reported in this manuscript.
EDAT- 2007/07/04 09:00
MHDA- 2007/10/19 09:00
PMCR- 2009/10/02
CRDT- 2007/07/04 09:00
PHST- 2007/03/01 00:00 [received]
PHST- 2007/04/11 00:00 [revised]
PHST- 2007/05/07 00:00 [accepted]
PHST- 2007/07/04 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/07/04 09:00 [entrez]
PHST- 2009/10/02 00:00 [pmc-release]
AID - S0306-4530(07)00115-1 [pii]
AID - 10.1016/j.psyneuen.2007.05.004 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2007 Jul;32(6):734-45. doi: 
      10.1016/j.psyneuen.2007.05.004. Epub 2007 Jul 2.